EGFR and hepatocellular carcinoma: Otherwise, in hepatocellular carcinoma (HCC), YTHDF2 acts as a tumor suppressor and promotes the degradation of epidermal growth factor receptor (EGFR) mRNA, and negatively modulates its stability [63].